Company Filing History:
Years Active: 2014
Title: Joachim Lupberger: Innovator in Antiviral Therapies
Introduction
Joachim Lupberger is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of antiviral therapies, particularly in the fight against hepatitis C virus (HCV) infections. His innovative work focuses on identifying cellular protein kinases as potential targets for medical intervention.
Latest Patents
Lupberger holds a patent titled "Host cell kinases as targets for antiviral therapies against HCV infection." This invention outlines several networks of cellular protein kinases that can be targeted for medical intervention against HCV and related diseases. The patent details therapeutic protocols and pharmaceutical compositions aimed at inhibiting the activity of these protein kinases to prevent and treat HCV infections. Additionally, it includes methods for identifying kinase inhibitors that may be utilized in the treatment and prevention of HCV-related diseases.
Career Highlights
Joachim Lupberger is affiliated with the National Institute of Health and Medical Research, where he conducts his research and development activities. His work has been instrumental in advancing the understanding of HCV and developing new therapeutic strategies.
Collaborations
Lupberger collaborates with Thomas Baumert, a fellow researcher in the field. Their partnership has contributed to the progress of antiviral research and the development of innovative treatment options.
Conclusion
Joachim Lupberger's contributions to antiviral therapies, particularly against HCV, highlight his role as an important inventor in the medical field. His patent on targeting host cell kinases represents a significant advancement in the fight against viral infections.